O2L-001
Pre-clinical- Indications
- Hemorrhagic stroke
Company intelligence / Profile preview
Op2Lysis
Boulogne-Billancourt, Île-de-France, Franceop2lysis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Op2Lysis develops novel thrombolytic therapies for hemorrhagic stroke using its proprietary NANOp2Lysis® nanoparticle drug delivery platform and an optimized tPA agent called OptPA. Their lead candidate, O2L‑001, aims to rapidly and safely remove intracerebral hematomas after hemorrhagic stroke, with a focus on improving efficacy while reducing neurotoxicity and bleeding risk. The company’s approach addresses significant unmet needs in acute stroke care by enabling safer clot dissolution within the brain. Clinical results are not yet published; programs appear to be at preclinical or early clinical stages.
- Therapeutic areas
- Neurology
- Modalities
- Thrombolytic agents (e.g., optimized tPA/OptPA)Nanoparticle-based drug delivery (NANOp2Lysis® platform)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Op2Lysis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Op2Lysis.